Alectinib vs Ensartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Alectinib · Alecensa
Marketed by Roche and partners
NCT02075840 · Phase 3 · completed
Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.
Next expected readout: November 2026 · NCT04302025 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 (From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)): Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019). (met)
Result source: NCT02838420
Ensartinib · Ensacove
Marketed by Xcovery Holdings and partners
NCT02767804 · Phase 3 · active, not recruiting
This was a randomized, phase 3, active-controlled trial with 290 patients comparing ensartinib to crizotinib, using progression-free survival (a hard clinical endpoint) as the primary measure, and the trial met its primary endpoint with a large, statistically significant improvement favoring ensartinib. However, the study was open-label (no blinding of patients or investigators), which limits confidence in outcome assessments despite the use of independent radiology review, so the evidence is graded as solid but not the highest tier.
Next expected readout: February 2027 · NCT05241028 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (36 months): eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. (met)
Result source: NCT02767804
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alectinib | Ensartinib |
|---|---|---|
| PFS, median | 10.9 vs 1.4vs Premetrexed/DocetaxelNCT026043425 other results
| —Trial running · NCT06955325 |
| OS, median | 81.1 vs 54.2vs CrizotinibNCT020758403 other results
| —Trial running · NCT06955325 |
| ORR | 82.9% vs 75.5%vs CrizotinibNCT020758409 other results
| —Trial running · NCT06955325 |
| Duration of response, median | 42.3 vs 11.1vs CrizotinibNCT020758403 other results
| —Trial running · NCT06955325 |
PFS, median
- Alectinib
- 10.9 vs 1.4vs Premetrexed/DocetaxelNCT02604342
5 other results
- 25.7 vs 10.4 NCT02075840
- 7.1 vs 1.6 NCT02604342
- 8.2 NCT01871805
- 8.4 NCT01871805
- 8.9 NCT01801111
- Ensartinib
- —Trial running · NCT06955325
OS, median
- Alectinib
- 81.1 vs 54.2vs CrizotinibNCT02075840
3 other results
- 27.8 NCT02604342
- 27.9 NCT01871805
- 29.2 NCT01801111
- Ensartinib
- —Trial running · NCT06955325
ORR
- Alectinib
- 82.9% vs 75.5%vs CrizotinibNCT02075840
9 other results
- 48.1% vs 0% NCT02604342
- 52.2% NCT01871805
- 50.8% NCT01801111
- 44.8% NCT01801111
- 52.9% NCT01871805
- 51.4% NCT01801111
- 50% NCT01801111
- 73.1% NCT01801111
- 57.1% NCT01801111
- Ensartinib
- —Trial running · NCT06955325
Duration of response, median
- Alectinib
- 42.3 vs 11.1vs CrizotinibNCT02075840
3 other results
- 14.9 NCT01871805
- 13.3 NCT01871805
- 15.2 NCT01801111
- Ensartinib
- —Trial running · NCT06955325
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Alectinib: 4 of 4 rows · Ensartinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alectinib | Ensartinib |
|---|---|---|
| Dropout rate | n/a: no completion milestonea NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more resultsn/a: no completion milestone NCT02838420 · Phase 3 · monotherapy 54.4% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT01801111 · Phase 1/2 —600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 0%225 mgb NCT01625234 · Phase 1/2 show 7 more results0%225 mg NCT01625234 · Phase 1/2 0%250 mg NCT01625234 · Phase 1/2 0%200 mg NCT01625234 · Phase 1/2 0%100 mg NCT01625234 · Phase 1/2 0%50 mg NCT01625234 · Phase 1/2 0%25 mg NCT01625234 · Phase 1/2 n/a: no completion milestone200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%a NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more results— NCT02838420 · Phase 3 · monotherapy — NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 8.7% NCT01801111 · Phase 1/2 —600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | —225 mgb NCT01625234 · Phase 1/2 show 7 more results—225 mg NCT01625234 · Phase 1/2 —250 mg NCT01625234 · Phase 1/2 —200 mg NCT01625234 · Phase 1/2 —100 mg NCT01625234 · Phase 1/2 —50 mg NCT01625234 · Phase 1/2 —25 mg NCT01625234 · Phase 1/2 50%200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 46.1%a NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more results15.2% NCT02838420 · Phase 3 · monotherapy 26% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 28.3% NCT01801111 · Phase 1/2 24.1%600 mg (Fed) NCT01871805 · Phase 1/2 · registry result, not featured evidence | 50%225 mgb NCT01625234 · Phase 1/2 show 7 more results43.6%225 mg NCT01625234 · Phase 1/2 50%250 mg NCT01625234 · Phase 1/2 54.5%200 mg NCT01625234 · Phase 1/2 40%100 mg NCT01625234 · Phase 1/2 33.3%50 mg NCT01625234 · Phase 1/2 25%25 mg NCT01625234 · Phase 1/2 50%200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a constipation 40.1% anaemia 27.6% blood bilirubin increased 24.3% NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 4 more resultsaspartate aminotransferase increased 52% blood bilirubin increased 48.8% blood creatine phosphokinase increased 44% NCT02838420 · Phase 3 · monotherapy constipation 20.8% anaemia 15.6% myalgia 14.3% NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 600 mg (Fed) fatigue 41.4% constipation 39.1% headache 28.7% NCT01871805 · Phase 1/2 · registry result, not featured evidence | show 7 more results200 mg hypoalbuminaemia 100% anaemia 50% arthralgia 50% NCT02898116 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alectinib
show 4 more results
show 1 more result
show 1 more result
show 1 more result
+ 635 further endpoints in the CSV export.
Ensartinib
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · Ensartinib's landscape